20 Apr 2018 07:00
Vectura Group plc
Directorate Change - Chief Financial Officer
Chippenham, UK - 20 April 2018: Vectura Group plc (LSE: VEC) ("Vectura" or the "Group"), an industry-leading device and formulation business for inhaled airways products, today announces that Chief Financial Officer and Executive Director Andrew Derodra has decided to leave the Group to take up a new role within the industry.
Andrew will take up the position of Chief Financial Officer at Unilabs, the private equity owned leader in medical diagnostics.
Andrew will remain in his position at Vectura and on the Board until the end of July in order to ensure a smooth transition process. A search for his replacement is underway and the Group will provide an update on his successor in due course.
James Ward-Lilley, Vectura's CEO, commented:
"I would like to thank Andrew both personally and on behalf of the Vectura Board for his continued support and contribution to the success of Vectura. Andrew played a key role in the business after joining Skyepharma in 2013, and later in bringing the Vectura and Skyepharma businesses together in 2016. He leaves the transformed Vectura Group in good shape and with a strong outlook, well-positioned to capitalise on the great opportunities with our inhaled in-market products and refocussed pipeline portfolio. We wish Andrew every success in his new role."
- Ends -
For more information, please contact:
Vectura Group plc | +44 (0)7471 352 720 |
|
|
David Ginivan - VP Corporate Communications Julia Wilson - Director Investor Relations |
|
Consilium Strategic Communications | +44 (0)20 3709 5700 |
Mary-Jane Elliott / Chris Welsh / Jessica Hodgson |
|
About Vectura
Vectura is an industry-leading inhaled product formulation, device design and development business offering a uniquely integrated inhaled drug delivery platform. We develop inhalation products to help patients suffering from airways diseases.
Vectura has eight key inhaled, two non-inhaled and ten oral products marketed by partners with growing global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Bayer, Chiesi, Almirall, Janssen, Dynavax and Tianjin KingYork.
Vectura's strategy is to fully leverage its differentiated technology and skills, maximising value by enhancing the delivery and performance of inhaled products and through the development of high-quality generic alternatives to branded therapies.
For further information, please visit Vectura's website at www.vectura.com.